

Media Contact:  
Drew Avril  
coActive Public Relations  
718-871-7117  
davril@coactivepr.com

## **SOLX Receives CE Approval for Implantable Gold Micro-Shunt**

### ***- DeepLight® Glaucoma Treatment System Now Available Internationally -***

BOSTON, October 15, 2005 – SOLX, Inc. announced that the 24-karat DeepLight Gold Micro-Shunt (GMS) has been granted CE approval and is available for sale outside the U.S. for the first time. The announcement came today at the 109th American Academy of Ophthalmology (AAO) annual meeting in Chicago, and GMS results to date have shown remarkable IOP reduction without a bleb.

“The treatment of open-angle glaucoma has changed little throughout the past two decades with conventional drug therapy and surgery accounting for the majority of today’s interventions,” said Gabriel Simon, MD, PhD, director of ophthalmic research at the Boston University Photonics Center and Research Professor of Biomedical Engineering at Boston University. “The need for less invasive, yet highly effective glaucoma treatments prompted our development of the gold micro-shunt – a tiny, bio-compatible implant that uses the eye’s natural pressure differential between the anterior chamber and suprachoroidal space to reduce IOP.”

GMS clinical results submitted to the authorized European authority’s notified body Intertek/Amtac included 70 eyes with open-angle glaucoma failed on maximum medical therapy as well as least one surgical intervention. During a minimally-invasive procedure, the ultra-thin GMS was inserted through a 4 mm-wide incision connecting the anterior chamber and the suprachoroidal space. Eyes in the study were followed for up to 2 years and have demonstrated more than 34% reduction compared to best medicated baseline. Complications and adverse events with the GMS were low and transient in almost all cases, especially as compared to the reported complications and adverse events associated with blebs.

“We consider today’s CE approval of the gold micro-shunt to be a major milestone for SOLX,” stated Doug Adams, President and CEO of SOLX. “Now that both components of the DeepLight Glaucoma Treatment System—the 790 Titanium Sapphire Laser and Gold Micro-Shunt—have been CE approved by the authorized European authority’s notified body, SOLX is one step closer to our goal of a future in which no glaucoma patient is required to take more than one medication.”

SOLX can be visited at booth number 227 at McCormick Place in Chicago from October 15 – 18 at the AAO annual meeting. More information on training and product availability is available at [www.solx.com](http://www.solx.com).

### **About the DeepLight® Glaucoma Treatment System**

The DeepLight Glaucoma Treatment System includes the DeepLight Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt (GMS), which can be used separately or together to provide patients with multiple options for maximum IOP reduction. The 790 titanium-sapphire solid-state laser was CE approved by the authorized European authority's notified body in December 2004 and has been shown to provide deeper tissue penetration than other lasers currently used in trabeculoplasty, to a depth of approximately 200 microns, without causing damage to the trabecular meshwork.

The GMS is a 24-karat gold ultra-thin (.44 microns thick, approximately one-third the thickness of a human hair) implant 5.8 mm long and 2 mm wide. The GMS is not a tube, but a flat plate designed for subsclearal implantation through a single micro-incision. It contains numerous micro-tubular channels and acts as a bridge between the anterior chamber and the suprachoroidal space, maximizing uveal scleral outflow through and around the device. The GMS rests permanently in the suprachoroidal space and cannot be felt by the patient. It is also bio-compatible, physically inert and has been shown to eliminate the formation of scar tissue.

### **About SOLX**

Based at the Boston University Photonics Center in Boston, Massachusetts, SOLX is a privately held company developing new approaches to glaucoma treatment. SOLX's DeepLight Glaucoma Treatment System is being developed to provide physicians with new tools to reduce intraocular pressure in glaucoma sufferers through its DeepLight 790 Titanium Sapphire Laser and DeepLight Gold Micro-Shunt (GMS). More information can be found online at [www.SOLX.com](http://www.SOLX.com).

### **About The Photonics Center at Boston University**

The Photonics Center at Boston University identifies and develops technologies based on the practical application of light. The Photonics Center hosts a Business Accelerator program that enables emerging photonics technology companies to grow from idea to commercialization with greater speed and success. The Photonics Center provides an entrepreneurial environment that includes 20 laboratories, workspace for up to 20 start-up companies, and access to a range of equipment worth in excess of \$40 million. For more information, please visit [www.thephotonicscenter.com](http://www.thephotonicscenter.com).